China Medicine Corporation (CHME.OB) - 500 Beiträge pro Seite

[benefactor [KommA]]

http://www.chinamedicinecorp.com

China Medicine Corporation (CMC) is a Delaware registered corporation, established in 2005. On February 8, 2006, the company acquired Guangzhou Konzern Medicine Co., Ltd as its wholly owned subsidiary. The company\'s name was changed from Lounsberry Holdings III, Inc to China Medicine Corporation on May 10, 2006.

Our mission is to become a leading research-driven pharmaceutical company in China dedicated to the discovery, development, manufacturing and distribution of pharmaceutical and nutritional supplement products.

We are proud of our strong research, development, and manufacturing capabilities. CMC strives to achieve the growth and market leadership through R & D capabilities, drug commercialization and selective acquisitions of research and manufacturing entities.

Guangzhou Konzern Medicine Co., Ltd is a medicine distributor conducting business in China to sell more than 1,100 medicine products nationwide, including, traditional Chinese medicine (finished medicine made of Chinese herbs), Chinese herbs and nutritional supplements. These products include both preion and non preion drugs. Konzern purchases its products from Chinese drug manufacturers sells its products to wholesale distributors, hospitals and retail drug stores. Konzern\'s sales network reaches 28 provinces, over 300 hospitals, 500 medicine companies and 1788 drug stores throughout China .

We believe, with the infusion of Western management skills, advanced technology, capital resources, the consolidation of the companies in its portfolio will have a stronger competitive position in the domestic and international pharmaceutical markets. With the fastest growing economy in the world, Chinese healthcare industry is undergoing a fundamental restructure, and Chinese pharmaceutical market will be the biggest potential market in the world. CMC aims to take advantage of the conditions within the industry and the surging demand for pharmaceutical and nutritional supplements products fueling economic growth.

[benefactor [KommA]]

China Medicine Announces Second Quarter 2007 Results
Tuesday August 14, 9:09 am ET

GUANGZHOU, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ --

Second Quarter Highlights:
-- Revenue increased 105% to $8.3 million
-- Operating income increased 313% to $1.4 million
-- Net Income increased 328% to $1.1 million or $0.08 per diluted share
-- First six months revenue increased 70.2% to $13.4 million with EPS of$0.15

China Medicine Corporation ("CMC") (OTC Bulletin Board: CHME - News), a leading distributor of prescription and over the counter pharmaceutical products, traditional Chinese medicines (finished medicines made of Chinese herbs), Chinese herbs, nutritional supplements, dietary supplements, medical supplies (revenue generated from the above business line is referred to as "Product Sales") and medical formulations (revenue generated from the sale of medical formulations is referred to as "Medical Formula Sales") today announced financial results for the second quarter ending June 30, 2007.

Revenue for the second quarter of 2007 increased 104.5 percent to $8.3 million compared to $4.0 million in 2006. Product Sales increased 95.2 percent during the quarter to $7.8 million with the year over year increase primarily related to the Company securing exclusive distribution rights to over 100 new drugs within the Guangdong Province in the first quarter of 2007. During the second quarter Iopamidol, a traditional pharmaceutical used for stomach radiography, was the largest component of Product Sales and represented approximately 13 percent of total revenue with the Company's top five products totaling $3.6 million or 43 percent of revenue.

Sales of proprietary products totaled $0.4 million for the second quarter 2007, representing an 8.1 percent increase from the same period last year with Levocarnitine, a traditional pharmaceutical used in cardiac muscle disease, accounting for 50 percent of this revenue. Sales of products for which the Company has exclusive distribution rights totaled $2.6 million in the second quarter, an increase of 61.5 percent from the second quarter of last year. Medical Formula Sales increased nearly seven-fold to $0.5 million from last year and 138 percent sequentially as the Company benefited from a large sale to a customer. During the second quarter the Company's top five customers accounted for $2.5 million or 30 percent of total revenue.

"We are pleased with our second quarter results as we continue to execute our business plan by both increasing our exclusive drug distribution portfolio while also expanding sales of proprietary products which have a positive impact on our overall level of profitability," commented Mr. Yang Senshan, CEO & President of CMC. "The over 700 drugs we gained exclusive rights to distribute back in April contributed nearly $3 million in revenue during the quarter and reinforce our ability to gain access to the most sought after drugs in the market while delivering adequate sell through to our expansive customer base."

Sales of prescription and over the counter medicines totaled $4.4 million during the second quarter, a 62.6 percent increase with over the counter medicines accounting for $2.3 million. Traditional Chinese Medicines sales were $3.1 million up 152.7 percent as compared to last year. Gross profit for the second quarter of 2007 increased 122.6 percent to $2.4 million resulting in gross margins of 29.1 percent for the second quarter of 2007 compared to 26.7 percent for the second quarter of last year with the primary improvement related to the new products obtained in 2007 which carry higher margins in addition to a larger contribution from Medical Formula Sales.

Operating income was $1.4 million for the quarter, an increase of 313.2 percent compared to the $0.3 million in 2006 with operating margins of 17.5 percent and 8.7 percent respectively. Net income increased 317.4 percent to $1.1 million with earnings per weighted average fully diluted share increasing 100 percent to $0.08 as compared to $0.3 million in net income and earnings of $0.04 per weighted average per fully diluted share in the second quarter of 2006 based on 14.2 million and 7.5 million shares respectively. During the second quarter 2007 the Company had an effective income tax of 23.5 percent, which was relatively unchanged versus last year in addition to a Value Added Tax (VAT) of 17.0 percent, which is deducted before reported revenues. On June 30, 2007 the Company had approximately 19.5 million fully diluted shares outstanding.

For the first six months of 2007 revenues increased 70.2 percent to $13.4 million from $7.8 million for the first half of 2006. Revenues from Product Sales were $12.6 million, an increase of 68.9 percent from the $7.5 million for the first half of 2006 with Medical Formula Sales increasing 97.4 percent to $0.7 million. Gross profit for the first six months of 2007 totaled $4.1 million compared to $2.4 million for the same period last year, an increase of 68.5 percent with gross margins relatively unchanged. Operating income increased 192.5 percent to $2.4 million with operating margins increasing 7.4 percent to 17.8 percent. During the first six months of 2006 the Company incurred $0.3 million in non-cash charges related to one time reverse merger expenses compared to no such expense this year. Net income increased 240.9 percent to $1.9 million with weighted average per fully diluted share increasing 114.3 percent to $0.15 as compared to $0.6 million and $0.07 last year.

"The second half of our calendar year is generally the strongest as customers build inventory to meet rising demand as we enter the winter season and approach the Chinese New Year," continued Mr. Yang. "With our broadened product portfolio we are well positioned to capitalize on this trend and anticipate that revenues and net income will show meaningful increases during the second half of this year compared to the first."

China Medicine ended the quarter with $2.7 million in cash compared to $0.4 million at the end of 2006. During the second quarter cash used in operations was $3.1 million due to the increase in inventory and advances to suppliers as the Company prepares for the seasonal increase in demand. Accounts receivable were $6.7 million and were slightly lower than the $7.0 million from the end of 2006, and are held with long-term customers. Working capital at the end of the quarter was $20.9 million as compared to $12.8 million on December 31, 2006 with shareholder equity increasing 63.6 percent from the end of 2006 to $21.5 million. During the second quarter, the Company received $2.9 million in warrant proceeds. The Company has approximately 4.1 million warrants and 1.4 million options outstanding which if exercised would bring the Company over $11.0 million in additional cash.

"We continue to make strides as it relates to expanding our proprietary product offering, specifically our Yutain Capsule which is a Traditional Chinese Medicine used to treat lung cancer," continued Mr. Yang. "We expect to apply for a clinical trial with the SFDA in the near term and our team is very encouraged by the initial results and potential market size."

Mr. Yang concluded, "The acquisition environment in China remains robust as there are many under capitalized companies that possess significant assets both from a proprietary product standpoint and manufacturing presence. We will continue to evaluate potential acquisitions as we look to add these key components to our business which we believe over time will strengthen our competitive positioning while enhancing our overall profitability."

[LeRenard]

Hi benefactor,

bin von den Perlen, die Du so ausgräbst, wirklich beeindruckt:
Sangamo, KSW....

Werde mich nun mal mit dieser hier beschäftigen.

Danke für den Tipp


Gruß,

LeRenard

[benefactor [KommA]]

Antwort auf Beitrag Nr.: 32.126.046 von LeRenard am 23.10.07 21:12:34

Ein EPS von $0.14 im dritten Quartal ist hervorragend. Die Zahlen vom letzten Jahr sind zudem nicht zum Vergleich geeignet, da sie 2006 mit $1,229,912 durch den Verkauf von Technologie (other income) zustande kamen. Die Margen sind auserdem völlig in Ordnung. Der Markt reagiert meiner Meinung nach völlig schwachsinnig.


China Medicine Announces Third Quarter 2007 Results
Monday November 12, 8:00 am ET
Third Quarter Highlights:
-- Revenue increased 66% compared to 3Q 2006 revenue of $12.6 million
-- Net Income decreased 3% compared to 3Q 2006 net income of $2.2 million, for earnings of $0.14 per diluted share

GUANGZHOU, China, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China Medicine Corporation (OTC Bulletin Board: CHME - News), a leading distributor of medical products, traditional pharmaceutical and Chinese medicines, herbs and dietary supplements, today announced financial results for the quarter ended September 30, 2007.

Revenue for the third quarter of 2007 increased 65.72% to $12.6 million compared to $7.6 million for the third quarter of 2006. Revenue from product sales for the third quarter 2007 was $11,904,525, an increase of $5,537,906, or 87%, from revenue of $6,366,619 for the third quarter of 2006. The company obtained exclusive regional distribution rights in China's Guangdong Province for 160 new products during the first nine months of 2007.

Medical formula sales were $684,413 and $1,229,912 for the three months ended September 30, 2007 and 2006, respectively. These amounts represent proceeds from the sale of certain technology and know-how relating to the production of medicines. We initially acquire the technology in an undeveloped state from other companies, undertake research and development to make improvements, and sell the improved technology to other drug manufacturers. The primary reason for the decrease in medical formula sales is that fewer new customers have signed contracts for medical formula sales in 2007. We believe this is due to action by the State Food and Drug Administration ("SFDA"), which must approve every transfer of ownership of a medical formula in China, and which recently enhanced its approval procedures by setting higher application criteria which require more time for review.

Gross profit for the third quarter of 2007 was $3,823,461, an increase of $716,985, or 23%, from $3,106,476 for the third quarter of 2006. Gross margin for the third quarter of 2007 was 30.37%, as compared with 40.89% for the third quarter of 2006. The decrease in gross margin was due primarily to increased sales of over-the-counter products in the third quarter of 2007, which have lower margins than the prescription drugs and other products we sold in the third quarter of 2006; and decreased medical formula sales in the third quarter of 2007, which have much higher margins than the regular products sales.

Research and development expenses were $336,794 for the third quarter of 2007 compared with $31,361 for the third quarter of 2006. In both periods, these expenses were used primarily for the pre-clinical study of the Yutian capsule, a traditional Chinese medicine designed for use in the treatment of lung cancer.

Selling, general and administrative expenses were $830,518 for the third quarter of 2007, an increase of $645,001 from $185,517 for the third quarter of 2006. The increase was mainly caused by the increased expenses in payroll and sales bonuses to sales representatives, marketing expenses, office rent and furnishings, transportation and trade shows.

Net income for the three months ended September 30, 2007 was $2,205,914, a decrease of $71,465 from $2,277,379 for the comparable period in 2006. The decrease was due primarily to increases in selling, general and administrative expenses and research and development expenses.

As of September 30, 2007, China Medicine had working capital of $23,574,193, an increase of $13,715,998, or 139%, from $9,858,195 as of September 30, 2006. The company received $5.7 million proceeds through the exercise of warrants during the first nine months of 2007, which increased the company's working capital. The company used cash of $1,844,778 in operations for the nine months ended September 30, 2007, an increase of $1,148,801 from the cash used for the comparable period of 2006. The increase in net cash used in operating activities was largely due to the increase of advances to suppliers and inventories related to our increased quantity of sales.

"Our third quarter results were consistent with our internal expectations," explained Mr. Senshan Yang, CEO of China Medicine. "We sold more OTC drugs during this quarter, which lowered our profit margin. But this is just a temporary result. We expect our profit margins to improve through our efforts to increase the sales of high-margin products, proprietary products and medical formulas in accordance with our long-term sales strategy. Our administrative expenses were relatively high in the third quarter because we obtained exclusive distribution rights in Guangdong Province for over 160 products from the beginning of this year. Greater expenditures are typically needed for the marketing of such new products, and these expenses will be decreased once the sales network is set up." Mr. Yang added, "we are undertaking a search for a bi-lingual CFO and a qualified investor relations firm, so that we may better communicate with investors, integrate our financial system and enhance our internal control system. We are confident of having a great year in 2007 and we expect continuing success in 2008."

[Sonnwinn]

Antwort auf Beitrag Nr.: 32.394.899 von benefactor am 12.11.07 16:21:41

Der Kurs ist bislang enttäuschend.

[benefactor [KommA]]

Antwort auf Beitrag Nr.: 32.614.420 von Sonnwinn am 29.11.07 15:35:36

Der Kurs ist wahrlich enttäuschend, aber an den Zahlen kann es eigentlich nicht liegen. Einfach mal abwarten und weiter beobachten. CPHI hatte Anfangs ja auch enorme Startschwierigkeiten, bezogen auf die Performance.

[staubundschatten]

Antwort auf Beitrag Nr.: 32.614.803 von benefactor am 29.11.07 15:58:44

Der Markt reagiert meiner Meinung nach völlig schwachsinnig.

es ist sehr interessant, dass du bei ptsh den anlegern ständig die augen für ihr "fehlinvest" öffnen möchtest und hier nun selbst einmal zum opfer deiner anlageentscheidung wirst.

zur erinnerung: im ptsh-thread hast du china medicine beim wert von 3,40 empfohlen. ungefähr im wortlaut "das wäre ein echtes invest"

aber immerhin: es zeichnet dich aus, dass du dich auch hinter ein irrationalerweise schlecht laufendes papier stellst. eine rolle, die ich dir nicht zugetraut hätte.

keine sorge, ich bin schon weg und habe auch keinen bedarf, mich hier unbeliebt zu machen. es sollte nur mal gesagt werden.